Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease

NCT05062330 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT05062330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05062330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2021
Completion date
March 4, 2022
Enrollment
361 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye